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Abstract
Background: Zoledronic acid-induced uveitis (ZAIU) is rare but severe, and has been recently considered part of an
acute phase reaction. Only 15 cases have been reported since 2005. Here we describe a case with macular edema,
which is the first reported case observed after long-term alendronate tolerance.
Case presentation: A 63-year-old Asian woman received her first intravenous zoledronic acid treatment for the
management of postmenopausal osteoporosis as a more convenient substitute for oral alendronate. Twenty-four
hours later, bilateral eye irritations, periorbital swelling, blurred vision, and diplopia presented. The complete blood
count and transaminase levels were normal, but the erythrocytic sedimentation, C-reactive protein, and serum C4
levels were elevated. On detailed ophthalmological examination, a diagnosis of bilateral acute uveitis and macular
edema in the right eye was made. The ocular symptoms were not improved until administration of topical and oral
steroids. Complete resolution was achieved. There was no rechallenge of bisphosphonates, and no recurrence at
6 months follow-up. Based on an extensive review, abnormal fundus is rarely reported, especially in cases of
macular edema. Rechallenge with zoledronic acid in five cases induced no additional uveitis, and changing the
medication to pamidronate in another patient was also tolerated. Interestingly, our patient suffered from uveitis
soon after intravenous zoledronate exposure after a two-year tolerance to oral alendronate.
Conclusions: This is the first report of zoledronic acid induced uveitis with macular edema after long-term
alendronate tolerance. Prior oral alendronate may not entirely prevent ZAIU. Steroids are usually necessary in the
treatment of ZAIU. Bisphosphonate rechallenge is not fully contraindicated, and prior steroid administration may be
a more reasonable treatment choice according to the available evidence.
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Background
Zoledronic acid is generally well-tolerated in the man-
agement of osteoporosis and other metabolic bone dis-
eases [1]. The most frequent adverse event is acute
phase reaction (APR), which occurs in nearly half of the
patients after zoledronate infusion, but usually lasts for a
short time with less severity [2]. Zoledronic acid-
induced uveitis (ZAIU) is rare; the incidence was re-
ported to be 0.8–1.1 % [3, 4]. Some severe cases have
presented with transient reduced visual acuity [5–14].
Previously, other bisphosphonates (pamidronate [15, 16],
alendronate [17], and clodronate [18]) have also been re-
ported to be associated with acute uveitis. Uveitis is not
commonly considered to be part of the APR, but they
occur within the same time frame, suggesting that it
may have a similar pathogenesis [2, 19, 20]. Stepwise re-
gression of a phase three clinical trial showed less APR
after zoledronate infusion in previous users of oral
bisphosphonates [21].
Due to the low incidence [3, 4], even a prospective
randomized study failed to document the risk factors of
ZAIU [3]. Presently, only 15 individual cases have been
reported [5–14, 22–25]. We describe a case accompan-
ied with right macular edema occurring during the man-
agement of postmenopausal osteoporosis with the
substitution of the more convenient orally administered
alendronate. To our knowledge, this is the first report of
ZAIU with macular edema, as well as the first report of
ZAIU after long-term alendronate tolerance.
Case presentation
Case report
A 63-year-old Asian woman received her first dose of
zoledronic acid (Aclasta®, 5 mg/100 mL solution; Novar-
tis, San Mateo, CA, USA) for postmenopausal osteopor-
osis. She suffered from a past hepatitis B virus infection.
In the past 2 years, she was on oral alendronate (70 mg,
once per week), and the patient regularly used calcium
and vitamin D supplements. Slit-lamp and fundoscopy
examinations before the application of zoledronic acid
revealed right epiretinal membrane and bilateral xero-
phthalmia. Twenty-four hours after the infusion (5 mg
in 100 mL normal saline over 15 min at a constant infu-
sion rate), she began experiencing multiple symptoms,
including fatigue and weakness, generalized aches and
pains, bilateral eye irritation, periorbital swelling, blurred
vision, and diplopia.
Upon examination, her best-corrected visual acuity
was 20/40 in the left eye and 20/60 in the right eye,
and her intraocular pressure was 17 mm Hg, bilat-
erally. Slit-lamp examination revealed conjunctival
hyperemia, ciliary injection, flare (2+), keratic precipi-
tates (±), and trace cells in the anterior chamber. Pos-
terior synechiae was also present. Fundus and optical
coherence tomography (OCT) examinations revealed
right macular edema (Fig. 1), and fluorescein angiog-
raphy showed hyperfluorescence of the optic disk.
Hematological exams of complete blood counts and
transaminase levels were normal. The erythrocyte
sedimentation was 95 mm/h, the C-reactive protein
was elevated to 2.69 mg/dL, and the serum C4 level
was slightly increased to 0.45 g/L. Bilateral acute uve-
itis was diagnosed and topical ganciclovir, pranopro-
fen, fluorometholone, and atropine were prescribed.
Two days later, the ocular symptoms worsened, and treat-
ment with retrobulbar injection of methylprednisolone
and oral prednisolone was started. The patient’s ocular
symptoms improved remarkably in the following 3 days,
when best-corrected visual acuity reestablished to 20/30
bilaterally, and flare, keratic precipitates, cells, and macu-
lar edema disappeared. The patient continued with oral
prednisolone, tapering slowly over the following 6 weeks.
She achieved complete resolution, with no rechallenge
and no recurrence at the 6 month follow-up.
Discussion
According to the Naranjo adverse drug reaction prob-
ability scale, in our case study a score of 8 indicates a
probable association between zoledronic acid and uve-
itis. Regarding previously published cases, a probable
[10] to definite [5] causality has been reported.
The National Osteoporosis Foundation (NOF) recom-
mends that any eye inflammation related to bisphospho-
nate should be reported to the healthcare provider as
soon as possible [26]. However, due to the low preva-
lence and lack of recognition, although recommended
by an ophthalmologist, the correct diagnosis was made
2 days after the onset of eye irritations, which worsened
the ocular symptoms of our patient, and eye drops of
antivirals were inappropriately prescribed. Fortunately,
all the ocular manifestations recovered promptly, includ-
ing the right macular edema.
Clinical features of 16 published cases (including our
case) with ZAIU are shown in Table 1. Eight cases suffered
from osteoporosis (including our case) [5–8, 13, 22, 23],
four with bone metastasis from malignant tumors
[9–11, 24], one with frontal hyperostosis and breast can-
cer [25], one with back and femur pain from the treatment
of monoclonal gammopathy of undetermined significance
(MGUS) [14], and the remaining two cases had risks of
osteopenia due to leuprolide treatment for prostate cancer
[12]. All the ocular manifestations occurred in 3 days.
Only two out of 16 patients had a past ocular history. Bi-
lateral eye involvement appeared in one-third of the pa-
tients, corresponding to a previous study [8]. The main
ocular symptoms and signs included eye pain, blurred
vision, diplopia, photophobia, lid edema, proptosis,
conjunctival chemosis, hyperemia, and ophthalmoplegia.
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Nearly half of the patients presented with systemic symp-
toms. Posterior synechiae was observed in 6 patients, and
most of the cases were cured. Choroidal folds [6] and vit-
reous haze [5] presented in some unusual cases. However,
abnormal fundus was rarely reported, especially macular
edema, as described in our case.
Corticosteroids are usually necessary for treatment.
Topical steroids and adequate treatment often lead in
most cases to full recovery, but a small portion of patients
only respond well to systemic use of steroids [8, 14]. No
deterioration of osteoporosis has been reported to be re-
lated with steroid treatment.
Fig. 1 Optical coherence tomography examinations revealed right macular edema in a postmenopausal women with ZAIU. Two days after the
intravenous administration of zoledronic acid, the examination of optical coherence tomography (OCT) revealed right macular edema with epiretinal
membrane (arrow) and a normal left macula
Table 1 Clinical features of the 16 published cases (including our case) with zoledronic acid induced uveitis
Case Age Eye involved Time from exposure to onset of ocular menifestations Indications Ocular history
1 [5] 66 unilateral 2d postmenopausal osteoporosis no
2 [6] 75 unilateral 2d osteoporosis no
3 [7] 58 unilateral NA osteoporosis no
4 [23] 58 unilateral 10 h osteoporosis no
5 [8] 56 unilateral 12 h postmenopausal osteoporosis no
6 [25] 70 unilateral 1d frontal hyperostosis after breast cancer no
7 [24] 54 bilateral 1d breast cancer with bone matastasis no
8 [9] 78 unilateral 48 h prostate cancer with bone matastasis no
9 [10] 48 unilateral 24 h breast cancer with bone matastasis no
10 [11] 54 unilateral 3d breast cancer with lung and bone matastasis no
11 [12] 56 bilateral 72 h prostate cancer treated with leuprolide no
12 [12] 68 bilateral 60 h prostate cancer treated with leuprolide no
13 [13] 60 unilateral 24 h osteoporosis and breast cancer yes
14 [14] 62 bilateral 48 h back and femur pain in MGUS no
15 [22] 59 unilateral 2d osteoporosis no
16a 63 bilateral 24 h postmenopausal osteoporosis yes
aThe case described in this report, NA not available, MGUS monoclonal gammopathy of undetermined significance
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Further use of bisphosphonates is not fully contraindi-
cated. From our review of previous reports, in five pa-
tients given zoledronic acid with or without the
protection of steroids, no additional ocular problems
were reported [4, 12, 20]. Pamidronate was also pre-
scribed to another patient, and a tolerance effect was
also observed with a prior combination of steroids [27].
Interestingly, our patient developed uveitis soon after
administration of intravenous zoledronate after a 2-year
tolerance to oral alendronate. This is the first report of
ZAIU after long-term alendronate tolerance.
Patel et al. retrospectively reported that 0.8 % of post-
menopausal women with osteopenia receiving zoledro-
nate developed mild to severe anterior acute uveitis [4].
More recently, the incidence of ZAIU was prospectively
reported to be 1.1 % [95 % confidence interval (CI) 0.5–
2.1] in a secondary analysis of a randomized controlled
trial of early postmenopausal women [3]. Regarding oral
bisphosphonates, a retrospective cohort study reported
the incidence rate to be 29/10,000 person-years for uve-
itis in 10,827 first time users [28]. The true incidence
might be higher, because some mild to moderate pa-
tients may fail to seek treatment.
APR is the most frequent adverse event after bisphos-
phonate use, usually including fever, fatigue, nasophar-
yngitis, musculoskeletal pain, and gastrointestinal
symptoms. All APR components had a peak onset within
1 day, and the median duration of the APR was 3 days
[21]. Recently, acute uveitis is being considered as part
of APR after bisphosphonate dispensing, due to its simi-
lar time of occurrence [4, 8]. Bisphosphonates have been
shown to share homologies with γ/δ T-cell ligands by
stimulating cytokine release by γ/δ lymphocytes, and by
inhibiting farnesyl diphosphate synthase to increase the
intracellular accumulation of isopentenyl pyrophosphate
[29]. These activities may contribute to the development
of APR and uveitis.
Reid et al. investigated 7,765 postmenopausal women
with osteoporosis, using a stepwise logistic regression
analysis, and showed that APRs were less common in
smokers, diabetics, calcitonin users, and previous oral
bisphosphonate users [21]. Because uveitis is a part of
APR, it seems to develop less frequently after oral bis-
phosphonate tolerance, as described in our case study.
Additional and larger case studies and single case re-
ports are still needed to confirm the risk factors of ZAIU
after previous bisphosphonate use.
Conclusions
We report a case of ZAIU with macular edema after long-
term oral alendronate tolerance. ZAIU is beginning to be
accepted as part of APR due to the similar time of occur-
rence. Endocrinologists and ophthalmologists should be
aware of this drug reaction, in cases of deterioration of
ocular symptoms and the inappropriate use of antibiotics
and antiviral agents. Prior oral alendronate may not en-
tirely prevent ZAIU. Steroids are usually necessary in the
treatment of ZAIU, and systemic steroids are sometimes
indicated. The readministration of bisphosphonate is not
fully contraindicated, but according to the available evi-
dence prior steroid protection may be a more reasonable
treatment strategy.
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